Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma
Massachusetts General Hospital
Massachusetts General Hospital
University of Washington
University of Washington
Columbia University
Dana-Farber Cancer Institute
Janssen Research & Development, LLC
MEI Pharma, Inc.
Amgen
Fondazione Italiana Linfomi - ETS
MEI Pharma, Inc.
Genmab
Hoffmann-La Roche
Academic and Community Cancer Research United
Xenikos
Columbia University
Altor BioScience
University of California, San Francisco
University of Chicago
Ipsen
Amgen
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Memorial Sloan Kettering Cancer Center
Stanford University
ADC Therapeutics S.A.
SecuraBio
SecuraBio
University of Nebraska
University of Nebraska
Gilead Sciences
TG Therapeutics, Inc.
Eastern Cooperative Oncology Group
Asana BioSciences
Fred Hutchinson Cancer Center
Medical College of Wisconsin
Regeneron Pharmaceuticals
Spectrum Pharmaceuticals, Inc
Spectrum Pharmaceuticals, Inc
Hoffmann-La Roche
Rush University Medical Center
Regeneron Pharmaceuticals
ADC Therapeutics S.A.
Spectrum Pharmaceuticals, Inc
Northwestern University
Columbia University
Fred Hutchinson Cancer Center
Gilead Sciences
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Baylor College of Medicine